EGFR and non-small cell lung carcinoma: The solution to the best treatment sequencing for patients harboring uncommon EGFR mutations may come from the ongoing phase II study CAPLAND (NCT04811001), which is exploring the best treatment sequencing of dacomitinib followed by or subsequent to osimertinib in patients with NSCLC harboring classical or uncommon EGFR mutations; furthermore, the efficacy of dacomitinib will be defined in patients with BMs.